Abstract Details

Title Demographic Profile of Spasticity within a Cohort of Post-Stroke Survivors

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P07 - (-)

Poster/Presentation
Number 235

Objective

Background BACKGROUND: PSS is a significant cause of post-stroke disability that leads to physical pain and deformity. Despite this, a paucity of literature describing these patients.

Design/Methods DESIGN/METHODS: Data from the 2005 Greater Cincinnati/Northern Kentucky Stroke Study (GCNKSS), a 5-county longitudinal study designed to characterize a verified ischemic stroke population, were utilized. PSS was defined as patient-reported spasticity at 3-month or 1-year assessments, while no-PSS was defined as no report of spasticity at either assessment. Data were collected via direct patient interview or chart extraction and were investigated for an association with subsequent spasticity. Groups were compared using chi-square, Fisher's exact, t-test, or Wilcoxon rank-sum test, as appropriate. Logistic regression was used to compare groups while adjusting for key variables.

Results RESULTS: Of those who completed the initial interview and reported spasticity status at subsequent assessments, 33% (78/236) reported spasticity. Significant differences in age, race, employment status, smoking status and median NIHSS were seen; PSS patients were younger (mean ±SD=60.9±13.9yrs vs 67.5±13.5yrs), more likely to be non-Caucasian (36 vs 23%), more commonly on disability (17 vs 6%), more likely to report current smokers (38 vs 22%), and had higher NIHSS (5 vs 4). Although not statistically significant (p=0.08), PSS patients tended to be more likely to have a history of prior stroke, after adjusting for age, gender, and race (OR=1.84, 95% CI: 0.93-3.66).

Conclusions CONCLUSIONS: Our data characterize the profile of patients with PSS. Further analyses are needed to identify potential confounders and explore causal relationships between stroke and spasticity development.

Authors/Disclosures
Theodore Wein, MD (Montreal General Hospital) PRESENTER	No disclosure on file
Aubrey Adams, PhD	Dr. Manack Adams has received personal compensation for serving as an employee of Abbvie. Dr. Manack Adams has stock in Abbvie.
	No disclosure on file
Patrick J. Gillard, PharmD, MS	Mr. Gillard has received personal compensation for serving as an employee of AbbVie. Mr. Gillard has stock in AbbVie.
Kathleen Alwell	No disclosure on file
	No disclosure on file
Daniel Woo, MD, FAAN (University at Buffalo)	The institution of Dr. Woo has received research support from NIH.
Pooja Khatri, MD, FAAN (Univ of Cincinnati/Dept of Neuro)	The institution of Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lumosa. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bayer. The institution of Dr. Khatri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Diamedica. Dr. Khatri has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Basking Biosciences. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Khatri has received research support from Cerenovus. Dr. Khatri has received publishing royalties from a publication relating to health care.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Matthew L. Flaherty, MD	Dr. Flaherty has received personal compensation for serving as an employee of Sense Diagnostics, Inc. Dr. Flaherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boeringher Engelheim. Dr. Flaherty has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Flaherty has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alexion. Dr. Flaherty has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for various law firms. Dr. Flaherty has stock in Sense Diagnostics, Inc. The institution of Dr. Flaherty has received research support from NINDS. Dr. Flaherty has received intellectual property interests from a discovery or technology relating to health care.
Opeolu Adeoye	No disclosure on file
Simona Ferioli, MD (UCMC)	Dr. Ferioli has nothing to disclose.
Joseph P. Broderick, MD, FAAN (University of Cincinnati)	The institution of Dr. Broderick has received research support from Novo Nordisk. Dr. Broderick has received publishing royalties from a publication relating to health care.
Dawn O. Kleindorfer, MD, FAAN (University of Michigan Department of Neurology)	Dr. Kleindorfer has nothing to disclose.
Brett M. Kissela, MD, MS, FAAN (University of Cincinnati Hospital)	The institution of Dr. Kissela has received research support from NIH/NINDS. Dr. Kissela has a non-compensated relationship as a Board Member with AHA Regional Board that is relevant to AAN interests or activities.

��ɫ��

��ɫ��